Oral alternative to eye injections? Novo backs startup’s big plan to repurpose shelved drug
For patients with diabetic retinopathy, anti-VEGF injections to the eye are often the only non-surgical option to stave off vision loss. But in recent years, several Big Pharma players — including Roche and Bayer — are beginning to test drugs that can be given orally.
A biotech startup out of Copenhagen wants to give them a run for their money.
Founded by Novo Seeds, Breye Therapeutics (rhymes with “eye”) is coming out of the gate with $4 million in seed funding from Novo Holdings and Sound Bioventures. Its lead drug comes from Zealand Pharma, where Breye CEO Ulrik Mouritzen served as head of clinical development before launching the new company in 2019.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.